PMBI has Launched a New Variant of Diabetes Medicines

A new type of diabetes medication at an affordable price has been introduced by PMBI as part of the Pradhan Mantri Jan Aushadhi Pariyojana.

Sitagliptin, a new form of diabetic medication, has been introduced by Ravi Dadhich, Chief Executive Officer of the Pharmaceutical and Medical Devices Bureau of India, for purchase by all individuals at reasonable prices under the Pradhan Mantri Janaushadhi Pariyojana.

In all of its Janaushadhi Kendras, PMBI has introduced a new version of the medication Sitagliptin and its combination.

Let us inform you that Jan Aushadhi Kendras would charge Rs 60 for each 50 mg sitagliptin phosphate tablet IP used to treat sugar diabetes. Simultaneously, the cost of a sitagliptin phosphate tablet IP 100 mg has remained unchanged at Rs 100. Sitagliptin + Metformin Hydrochloride Tablet 50 mg/500 mg is also priced at Rs 65. Sitagliptin + Metformin Hydrochloride Tablets, 50 mg/1000 mg, are available for purchase for Rs. 70.

Good news for diabetics

In order to enhance glycemic control in type-2 individuals, sitagliptin has been found to be an addition to diet and exercise. Given that they can be purchased at other medical supply outlets for between Rs. 162 and Rs. 258, the prices of these medications in Pradhan Mantri Janaushadhi Kendras will be 60 to 70 percent less than those of the branded firms now present in the market.

Medicines will be available here at cheap rates

Significantly, more than 8700 Pradhan Mantri Bhartiya Janaushadhi Kendras have been established across the nation as a result of the Pradhan Mantri Bhartiya Janaushadhi Yojana. These stores offer top-notch generic medications, medical equipment, nutraceuticals, and other goods. These clinics currently stock more than 1600 medications and 250 surgical tools, including Suvidha sanitary pads that are offered for sale at Re 1 per pad.

The Modi administration offers affordable vital medications at PMBI Janaushadhi Kendras. To guarantee that residents have frequent access to appropriate supplies of good-quality, reasonably priced critical medications, ongoing measures are being made.